Sequential hepatogenic transdifferentiation of adipose tissue-derived stem cells: relevance of different extracellular signaling molecules, transcription factors involved, and expression of new key marker genes.
Adipose tissue contains a mesenchymal stem cell (MSC) population known as adipose-derived stem cells (ASCs) capable of differentiating into different cell types. Our aim was to induce hepatic transdifferentiation of ASCs by sequential exposure to several combinations of cytokines, growth factors, and hormones. The most efficient hepatogenic protocol includes fibroblastic growth factors (FGF) 2 and 4 and epidermal growth factor (EGF) (step 1), hepatocyte growth factor (HGF), FGF2, FGF4, and nicotinamide (Nic) (step 2), and oncostatin M (OSM), dexamethasone (Dex), and insulin-tranferrin-selenium (step 3). This protocol activated transcription factors [GATA6, Hex, CCAAT/enhancer binding protein alpha and beta (CEBPalpha and beta), peroxisome proliferator-activated receptor-gamma, coactivator 1 alpha (PGC1alpha), and hepatocyte nuclear factor 4 alpha (HNF4alpha)], which promoted a characteristic hepatic phenotype, as assessed by new informative markers for the step-by-step hepatic transdifferentiation of hMSC [early markers: albumin (ALB), alpha-2-macroglobuline (alpha2M), complement protein C3 (C3), and selenoprotein P1 (SEPP1); late markers: cytochrome P450 3A4 (CYP3A4), apolipoprotein E (APOE), acyl-CoA synthetase long-chain family member 1 (ACSL1), and angiotensin II receptor, type 1 (AGTR1)]. The loss of adipose adult stem cell phenotype was detected by losing expression of Thy1 and inhibitor of DNA binding 3 (Id3). The reexpression of phosphoenolpyruvate corboxykinase (PEPCK), apolipoprotein C3 (APOCIII), aldolase B (ALDOB), and cytochrome P450 1A2 (CYP1A2) was achieved by transduction with a recombinant adenovirus for HNF4alpha and finally hepatic functionality was also assessed by analyzing specific biochemical markers. We conclude that ASCs could represent an alternative tool in clinical therapy for liver dysfunction and regenerative medicine.
Bonora-Centelles
A
A
Unidad de Hepatología Experimental, Centro de Investigación, Hospital La Fe, Valencia, Spain.
Jover
R
R
Mirabet
V
V
Lahoz
A
A
Carbonell
F
F
Castell
J V
JV
Gómez-Lechón
M J
MJ
D000273:Adipose Tissue / Q000166:cytology*; D054338:Cell Transdifferentiation; D002478:Cells, Cultured; D003907:Dexamethasone / Q000494:pharmacology; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D005434:Flow Cytometry; D020869:Gene Expression Profiling; D056945:Hep G2 Cells; D017228:Hepatocyte Growth Factor / Q000494:pharmacology; D051557:Hepatocyte Nuclear Factor 4 / Q000235:genetics / Q000378:metabolism; D022781:Hepatocytes / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000378:metabolism*; D009536:Niacinamide / Q000494:pharmacology; D053683:Oncostatin M / Q000494:pharmacology; D012643:Selenium / Q000494:pharmacology; D015398:Signal Transduction; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D014168:Transferrin / Q000494:pharmacology
D051557:Hepatocyte Nuclear Factor 4; D007328:Insulin; D014157:Transcription Factors; D014168:Transferrin; D053683:Oncostatin M; D009536:Niacinamide; D005346:Fibroblast Growth Factors; D017228:Hepatocyte Growth Factor; D003907:Dexamethasone; D012643:Selenium